COPENHAGEN, September 13 /PRNewswire/ --

- Summary: Genmab Signs Asset Exchange Agreement

Genmab A/S (OMX: GEN) announced today the execution of an asset exchange
agreement with Medarex, Inc. Under the terms of the agreement, Genmab will
receive full rights to HuMax-Inflam(TM)/MDX-018, which targets IL-8, and
Medarex will receive full rights to multiple disease programs in oncology.
Genmab and Medarex will release to each other all previously held economic
interests in the assets exchanged.

"Genmab will now hold all the rights to the HuMax-Inflam antibody which
we have developed in cooperation with Medarex and hope to move the product
into further clinical studies soon," said Lisa N. Drakeman, Ph.D., Chief
Executive Officer of Genmab.

About Genmab A/S

Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery and
development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future, we
remain committed to our primary goal of improving the lives of patients who
are in urgent need of new treatment options. For more information on Genmab's
products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.